189 related articles for article (PubMed ID: 27903457)
21. Inhibition of albendazole crystallization in poly(vinylpyrrolidone) solid molecular dispersions.
Kalaiselvan R; Mohanta GP; Manna PK; Manavalan R
Pharmazie; 2006 Jul; 61(7):618-24. PubMed ID: 16889070
[TBL] [Abstract][Full Text] [Related]
22. Physical stability of the amorphous state of loperamide and two fragment molecules in solid dispersions with the polymers PVP-K30 and PVP-VA64.
Weuts I; Kempen D; Decorte A; Verreck G; Peeters J; Brewster M; Van den Mooter G
Eur J Pharm Sci; 2005 Jun; 25(2-3):313-20. PubMed ID: 15911228
[TBL] [Abstract][Full Text] [Related]
23. Co-former selection for co-amorphous drug-amino acid formulations.
Kasten G; Löbmann K; Grohganz H; Rades T
Int J Pharm; 2019 Feb; 557():366-373. PubMed ID: 30578980
[TBL] [Abstract][Full Text] [Related]
24. Molecular insights into the formation of drug-monoacyl phosphatidylcholine solid dispersions for oral delivery.
Gautschi N; Van Hoogevest P; Kuentz M
Eur J Pharm Sci; 2017 Oct; 108():93-100. PubMed ID: 27240778
[TBL] [Abstract][Full Text] [Related]
25. Crystallization kinetics and molecular mobility of an amorphous active pharmaceutical ingredient: A case study with Biclotymol.
Schammé B; Couvrat N; Malpeli P; Delbreilh L; Dupray V; Dargent É; Coquerel G
Int J Pharm; 2015 Jul; 490(1-2):248-57. PubMed ID: 26003417
[TBL] [Abstract][Full Text] [Related]
26. Development of spray-dried co-precipitate of amorphous celecoxib containing storage and compression stabilizers.
Dhumal RS; Shimpi SL; Paradkar AR
Acta Pharm; 2007 Sep; 57(3):287-300. PubMed ID: 17878109
[TBL] [Abstract][Full Text] [Related]
27. The Stabilization of Amorphous Zopiclone in an Amorphous Solid Dispersion.
Milne M; Liebenberg W; Aucamp M
AAPS PharmSciTech; 2015 Oct; 16(5):1190-202. PubMed ID: 25732372
[TBL] [Abstract][Full Text] [Related]
28. Dielectric study of the molecular mobility and the isothermal crystallization kinetics of an amorphous pharmaceutical drug substance.
Alie J; Menegotto J; Cardon P; Duplaa H; Caron A; Lacabanne C; Bauer M
J Pharm Sci; 2004 Jan; 93(1):218-33. PubMed ID: 14648651
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Stability of New Co-Amorphous Drug Binary Systems: Study of Glass Transitions as a Function of Composition and Shelf Time.
Martínez LM; Videa M; Sosa NG; Ramírez JH; Castro S
Molecules; 2016 Dec; 21(12):. PubMed ID: 27983640
[TBL] [Abstract][Full Text] [Related]
30. Drug-polymer interaction and its significance on the physical stability of nifedipine amorphous dispersion in microparticles of an ammonio methacrylate copolymer and ethylcellulose binary blend.
Huang J; Wigent RJ; Schwartz JB
J Pharm Sci; 2008 Jan; 97(1):251-62. PubMed ID: 17724668
[TBL] [Abstract][Full Text] [Related]
31. A classification system to assess the crystallization tendency of organic molecules from undercooled melts.
Baird JA; Van Eerdenbrugh B; Taylor LS
J Pharm Sci; 2010 Sep; 99(9):3787-806. PubMed ID: 20623696
[TBL] [Abstract][Full Text] [Related]
32. Amorphous Sulfadoxine: A Physical Stability and Crystallization Kinetics Study.
Aucamp M; Milne M; Liebenberg W
AAPS PharmSciTech; 2016 Oct; 17(5):1100-9. PubMed ID: 26531745
[TBL] [Abstract][Full Text] [Related]
33. Classification of solid dispersions: correlation to (i) stability and solubility (ii) preparation and characterization techniques.
Meng F; Gala U; Chauhan H
Drug Dev Ind Pharm; 2015; 41(9):1401-15. PubMed ID: 25853292
[TBL] [Abstract][Full Text] [Related]
34. Molecular mobility-based estimation of the crystallization rates of amorphous nifedipine and phenobarbital in poly(vinylpyrrolidone) solid dispersions.
Aso Y; Yoshioka S; Kojima S
J Pharm Sci; 2004 Feb; 93(2):384-91. PubMed ID: 14705195
[TBL] [Abstract][Full Text] [Related]
35. Physical Stabilization of Pharmaceutical Glasses Based on Hydrogen Bond Reorganization under Sub-T
Tominaka S; Kawakami K; Fukushima M; Miyazaki A
Mol Pharm; 2017 Jan; 14(1):264-273. PubMed ID: 28043129
[TBL] [Abstract][Full Text] [Related]
36. Physics of amorphous solids.
Hilden LR; Morris KR
J Pharm Sci; 2004 Jan; 93(1):3-12. PubMed ID: 14648630
[TBL] [Abstract][Full Text] [Related]
37. Is a distinctive single Tg a reliable indicator for the homogeneity of amorphous solid dispersion?
Qian F; Huang J; Zhu Q; Haddadin R; Gawel J; Garmise R; Hussain M
Int J Pharm; 2010 Aug; 395(1-2):232-5. PubMed ID: 20562003
[TBL] [Abstract][Full Text] [Related]
38. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids.
Shah B; Kakumanu VK; Bansal AK
J Pharm Sci; 2006 Aug; 95(8):1641-65. PubMed ID: 16802362
[TBL] [Abstract][Full Text] [Related]
39. Predicting Glass-Forming Ability of Pharmaceutical Compounds by Using Machine Learning Technologies.
Jiang J; Ouyang D; Williams RO
AAPS PharmSciTech; 2023 Apr; 24(5):103. PubMed ID: 37072563
[TBL] [Abstract][Full Text] [Related]
40. The Slow Relaxation Dynamics in the Amorphous Pharmaceutical Drugs Cimetidine, Nizatidine, and Famotidine.
Viciosa MT; Moura Ramos JJ; Diogo HP
J Pharm Sci; 2016 Dec; 105(12):3573-3584. PubMed ID: 27773524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
